|Assessment Status||Rapid Review Complete|
|Drug||Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide|
|Indication||Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year|
|Rapid review commissioned||21/06/2023|
|Rapid review completed||19/07/2023|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Trimbow® for this indication not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.